Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 1 de 1
Filtrar
Mais filtros

Base de dados
Ano de publicação
Tipo de documento
Intervalo de ano de publicação
1.
J Pediatr Hematol Oncol ; 46(7): e528-e530, 2024 Oct 01.
Artigo em Inglês | MEDLINE | ID: mdl-39141797

RESUMO

BACKGROUND: Infantile myofibromatosis (IM) is a rare disorder characterized by benign tumors in the skin, subcutaneous tissue, muscle, and occasionally viscera. IM can be hereditary due to PDGFRB or NOTCH3 variants. Treatment is mainly conservative or surgical. Combination regimens have been used in case of disseminated disease. OBSERVATION: We present relapsed disease of IM 11 years after diagnosis in a 2-year-old child initially treated by microscopically complete resection. A new heterozygous c.1687G>A (p.Glu563Lys) mutation in the PDGFRB gene was identified (considered likely pathogenic). CONCLUSIONS: In association with initial treatment, genetic testing is crucial for tailored clinical practice and follow-up in patients diagnosed with IM.


Assuntos
Miofibromatose , Receptor beta de Fator de Crescimento Derivado de Plaquetas , Humanos , Miofibromatose/congênito , Miofibromatose/genética , Miofibromatose/patologia , Miofibromatose/diagnóstico , Pré-Escolar , Receptor beta de Fator de Crescimento Derivado de Plaquetas/genética , Masculino , Mutação , Recidiva Local de Neoplasia/genética , Recidiva Local de Neoplasia/patologia , Recidiva , Feminino
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA